Home/Pipeline/Precision Medicine Organoid Workflow

Precision Medicine Organoid Workflow

Various Cancers (e.g., Breast, Ovarian, Gastric) & Disease Modeling

Research/DiscoveryActive

Key Facts

Indication
Various Cancers (e.g., Breast, Ovarian, Gastric) & Disease Modeling
Phase
Research/Discovery
Status
Active
Company

About TheWell Bioscience

TheWell Bioscience has established itself as a provider of advanced, xeno-free hydrogel systems for 3D cell culture and biomanufacturing. Its core VitroGel® platform is a room-temperature-stable, synthetic ECM designed for ease of use, lot-to-lot consistency, and adaptability across research and development workflows, from basic research to GMP-ready production. The company targets three primary markets: precision medicine (drug discovery/personalized medicine), cell therapy (injectable carriers, organoid development), and biomanufacturing (scalable production of cells and tissues). With over 345 referenced publications, the technology is gaining traction in the research community as a tool to reduce variability and accelerate translation.

View full company profile